Nektar Therapeutics (NASDAQ:NKTR) Expected to Post Earnings of -$0.85 Per Share

Equities research analysts predict that Nektar Therapeutics (NASDAQ:NKTRGet Rating) will announce ($0.85) earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($1.15). Nektar Therapeutics posted earnings per share of ($0.69) in the same quarter last year, which would suggest a negative year-over-year growth rate of 23.2%. The business is scheduled to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Nektar Therapeutics will report full year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($3.19) to ($2.16). For the next year, analysts forecast that the business will post earnings of ($1.25) per share, with EPS estimates ranging from ($2.28) to ($0.27). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTRGet Rating) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.23. Nektar Therapeutics had a negative return on equity of 65.64% and a negative net margin of 476.58%. The business had revenue of $24.82 million during the quarter, compared to analysts’ expectations of $24.89 million. During the same quarter in the previous year, the business earned ($0.68) EPS. The company’s revenue for the quarter was up 5.0% on a year-over-year basis.

NKTR has been the subject of a number of research reports. William Blair cut Nektar Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 14th. JPMorgan Chase & Co. decreased their target price on Nektar Therapeutics from $24.00 to $17.00 in a report on Tuesday, March 1st. BTIG Research cut Nektar Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, March 14th. The Goldman Sachs Group cut Nektar Therapeutics from a “neutral” rating to a “sell” rating and set a $3.00 price target for the company. in a report on Monday, April 18th. Finally, Cowen cut Nektar Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $35.00 to $8.00 in a report on Monday, March 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Nektar Therapeutics has a consensus rating of “Hold” and an average target price of $13.46.

In related news, insider Jonathan Zalevsky sold 10,912 shares of the company’s stock in a transaction that occurred on Wednesday, February 16th. The stock was sold at an average price of $10.95, for a total transaction of $119,486.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Gil M. Labrucherie sold 7,579 shares of the company’s stock in a transaction that occurred on Wednesday, February 16th. The shares were sold at an average price of $10.95, for a total value of $82,990.05. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,186 shares of company stock worth $418,137. 2.91% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. Bellevue Group AG increased its position in Nektar Therapeutics by 8.0% in the first quarter. Bellevue Group AG now owns 4,808,401 shares of the biopharmaceutical company’s stock worth $25,917,000 after buying an additional 356,708 shares during the period. Verition Fund Management LLC acquired a new stake in Nektar Therapeutics in the first quarter worth $55,000. Charles Schwab Investment Management Inc. increased its position in Nektar Therapeutics by 1.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 947,937 shares of the biopharmaceutical company’s stock worth $5,109,000 after buying an additional 17,070 shares during the period. Edgestream Partners L.P. increased its position in Nektar Therapeutics by 1,457.7% in the first quarter. Edgestream Partners L.P. now owns 623,707 shares of the biopharmaceutical company’s stock worth $3,362,000 after buying an additional 583,667 shares during the period. Finally, First Trust Advisors LP increased its position in Nektar Therapeutics by 28.4% in the first quarter. First Trust Advisors LP now owns 4,390,618 shares of the biopharmaceutical company’s stock worth $23,665,000 after buying an additional 970,889 shares during the period. 93.08% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:NKTR opened at $3.99 on Friday. Nektar Therapeutics has a 1 year low of $3.52 and a 1 year high of $19.37. The stock has a market capitalization of $743.23 million, a P/E ratio of -1.49 and a beta of 1.36. The stock has a 50-day simple moving average of $5.49 and a 200-day simple moving average of $10.03.

Nektar Therapeutics Company Profile (Get Rating)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19.

Recommended Stories

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.